Clinical Research Directory
Browse clinical research sites, groups, and studies.
Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
Sponsor: Second Affiliated Hospital of Guangzhou Medical University
Summary
Tumor infiltration lymphocytes (TILs) have been harvested from advanced cancer patients and constructed to knockout PD1 gene and express scFvs against both PD1 and CTALA4 and CARs against various antigens, followed by transfusion into the patients. The safety, tolerance, and preliminary clinical efficacy of the TILs will be evaluated.
Official title: Engineered TILs/CAR-TILs With PD1 Knockout and Anti-PD1/CTLA4-scFv Secreting or CARs Against Various Antigens to Treat Advanced Solid Tumors
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2021-01-01
Completion Date
2035-01-01
Last Updated
2024-06-25
Healthy Volunteers
No
Conditions
Interventions
TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3
TILs and CAR-TILs injection: 1-10×10e7/kg cells for each treatment; 3 or more cycles.
Locations (1)
Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, China